Novel risk scoring system for patients with metastatic castration-resistant prostate cancer treated with lutetium-177–PSMA-617
The Oncologist · 08.07.2026 · 31 (8)
DOI: 10.1093/oncolo/oyag269 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 11.07.2026. Verfasst von Margo B Gerke und 19 weiteren Autor:innen. Beteiligte Einrichtung: Emory University School of Medicine, Atlanta, GA 30322, United States. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Dipeptides, Heterocyclic Compounds, 1-Ring, Lutetium. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health/National Cancer Institute.
Abstract (Originalsprache)
Purpose
Lutetium-177(177Lu)–PSMA-617 improves survival for patients with metastatic castration-resistant prostate cancer, but outcomes are heterogeneous and standardized risk stratification tools are lacking. We developed a novel risk stratification tool for patients treated with 177Lu–PSMA-617.
Methods
We conducted a retrospective analysis of 163 patients at Emory Winship Cancer Institute. Four prognostic models using Cox proportional hazards models were constructed using best-subset variable selection and integrated into a composite model.
Results
Among the 163 patients (52% White, 44% Black; 80% previous taxane use) body mass index decline during treatment was associated with shorter progression-free survival (PFS) and overall survival (OS) (HR = 1.75, P = .03; HR = 2.35, P = .031). Higher subcutaneous adipose tissue index (SATI)/skeletal muscle index (SMI) was independently associated with improved OS (HR = 0.5, P = .019), whereas higher visceral adipose tissue index (VATI)/SATI was independently associated with worse OS (HR = 2.62, P = .005). A body composition-based prognostic score identified VATI/SATI, SMI, and total adiposity as the strongest OS predictors (C = 0.629). The composite score incorporating inflammatory biomarkers and body composition demonstrated good discrimination (C-index = 0.732) and effectively stratified patients by PFS and OS. For PFS, relative risks across increasing risk quartiles were 0.34, 0.40, and 0.62 in compared with the highest risk quartile (P = .034). For OS, corresponding hazard ratios were 0.15, 0.19, and 0.54 (P = .003).
Conclusions
A risk score incorporating body composition and inflammatory biomarkers demonstrates prognostic value for patients treated with 177Lu–PSMA-617.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Emory University School of Medicine, Atlanta, GA 30322, United States.
- Biostatistics Shared Resource, Winship Cancer Institute, Emory University, Atlanta, GA 30322, United States.
- Department of Radiology and Imaging Sciences, Division of Nuclear Medicine and Molecular Imaging, Emory University, Atlanta, GA 30322, United States.
- Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, United States.
- Winship Cancer Institute of Emory University, Atlanta, GA 30322, United States.
- Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA 30322, United States.
ORCID-Profile: Margo B Gerke, Angelo Marra, Akshay Bedmutha, Jacob E Berchuck, Jordan Alana Ciuro, Saima Muzahir, Yuan Liu, Mehmet Asim Bilen
Förderung
- NCI NIH HHS
- National Institutes of Health/National Cancer Institute
Zitieren
APA
Gerke, M. B., Marra, A., Jayaraj, M., Yildrim, A., Bedmutha, A., Brown, J. T., Nazha, B., Berchuck, J. E., Parikh, R. B., Ahmed, S., Ciuro, J. A., Hartman, C., McClintock, G. R., Caulfield, S., Kucuk, O., Carthon, B. C., Schuster, D. M., Muzahir, S., Liu, Y., & Bilen, M. A. (2026). Novel risk scoring system for patients with metastatic castration-resistant prostate cancer treated with lutetium-177–PSMA-617. The Oncologist, 31(8). https://doi.org/10.1093/oncolo/oyag269
Vancouver
Gerke MB, Marra A, Jayaraj M, Yildrim A, Bedmutha A, Brown JT, et al. Novel risk scoring system for patients with metastatic castration-resistant prostate cancer treated with lutetium-177–PSMA-617. The Oncologist. 2026;31(8). doi:10.1093/oncolo/oyag269
BibTeX
@article{Gerke2026,
author = {Gerke, Margo B and Marra, Angelo and Jayaraj, Michelle and Yildrim, Ahmet and Bedmutha, Akshay and Brown, Jacqueline T and Nazha, Bassel and Berchuck, Jacob E and Parikh, Ravi Bharat and Ahmed, Shahid and Ciuro, Jordan Alana and Hartman, Caitlin and McClintock, Greta Russler and Caulfield, Sarah and Kucuk, Omer and Carthon, Bradley Curtis and Schuster, David M and Muzahir, Saima and Liu, Yuan and Bilen, Mehmet Asim},
title = {Novel risk scoring system for patients with metastatic castration-resistant prostate cancer treated with lutetium-177–PSMA-617},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {8},
doi = {10.1093/oncolo/oyag269}
}
EUVIMED